NAMSNewAmsterdam Pharma Company N.V. Ordinary Shares

CSNasdaq (XNAS)·USD

Identity

Security key: 18988
Ticker: NAMS
Type: CS — Common Stock
Exchange: Nasdaq(XNAS)
Venue group: NASDAQ
Operating MIC: XNAS
Market: stocks
Locale: us
Currency: USD
Listed: 2022-11-23
Round lot: 100
Active: Yes
Last seen in a load: 2026-08-14 20:49
Vendor updated: 2026-08-13 06:09
Ticker root / suffix: NAMS

Detail

Enriched 2026-08-14 20:47

Market cap: $3,326,719,413.27
Shares outstanding (class): 119,537,169
Shares outstanding (weighted): 119,537,169
SIC: 2834 PHARMACEUTICAL PREPARATIONS
Employees: 100
Location: NARRDEN, P7
Homepage: https://www.newamsterdampharma.com
Description: NewAmsterdam Pharma Co NV is a late-stage biopharmaceutical company with a mission to improve patient care in populations with metabolic diseases where currently approved therapies have not been adequate or well tolerated. Its product, obicetrapib, is a next-generation, oral, low-dose CETP inhibitor that is developed to potentially overcome the limitations of current LDL-C lowering treatments. The Company has one reportable segment, which comprises the discovery, development, and commercialization of transformative therapies for cardio-metabolic diseases.

Market cap and share counts drift.

Funds holding this security

55 funds · 58 positions · $464.87M reported value, as of 2026-03-31

All holders →

Fund	Ticker	Position value	% of fund	Balance	Match
SMALLCAP World Fund Inc SMALLCAP World Fund Inc	—	$268.76M	0.33%	8,396,080 NS	TICKER
Fidelity Contrafund Fidelity Contrafund	—	$40.64M	0.03%	1,269,492 NS	TICKER
iShares Biotechnology ETF iShares Trust	IBB	$17.21M	0.21%	537,784 NS	TICKER
PGIM Jennison Small Company Fund Prudential Jennison Small Co Fund, Inc.	—	$15.91M	0.50%	497,034 NS	TICKER
JPMorgan Small Cap Growth Fund JPMorgan Trust II	—	$14.37M	0.66%	448,876 NS	TICKER
Columbia Acorn Fund COLUMBIA ACORN TRUST	—	$11.63M	0.52%	363,308 NS	TICKER
abrdn Healthcare Investors —	—	$10.94M	0.96%	341,705 NS	TICKER
abrdn World Healthcare Fund —	—	$10.82M	2.25%	337,911 NS	TICKER
Fidelity Contrafund K6 Fidelity Contrafund	—	$8.79M	0.03%	274,556 NS	TICKER
Fidelity Fund Fidelity Hastings Street Trust	—	$7.80M	0.09%	243,800 NS	TICKER
BNY Mellon Small/Mid Cap Growth Fund BNY Mellon Investment Funds I	—	$5.71M	0.75%	178,388 NS	TICKER
AST Small-Cap Equity Portfolio Advanced Series Trust	—	$5.27M	0.28%	164,488 NS	TICKER
abrdn Life Sciences Investors —	—	$5.04M	0.90%	157,389 NS	TICKER
JPMorgan Small Cap Blend Fund JPMorgan Trust I	—	$4.64M	0.32%	144,914 NS	TICKER
VIP Health Care Portfolio Variable Insurance Products Fund IV	—	$3.68M	0.37%	115,000 NS	TICKER

How positions resolve to the securities master. FIGI_COMPOSITE is exact identifier equality — both sides got the FIGI from Bloomberg. TICKER is a narrow fallback used only where the master row carries no FIGI at all (2,389 rows do not, disproportionately Irish-domiciled US listings like LIN and ACN). Roughly 22% of all positions resolve to the master.

This match is a candidate, not a mapping. N-PORT tickers are filer-entered free text and collide with delisted and foreign symbols. Only 13% of positions carry a ticker at all. Good enough to ask which funds report holding a symbol; not good enough to build exposure reporting on. Prefer the ISIN-resolved link, which is marked FIGI_COMPOSITE.

Funds holding this security

Identifiers

master.security_identifier

TICKERNAMS
CIK0001936258
ISINNL00150012L7
Resolved through OpenFIGI from a holdings ISIN, not supplied by the securities vendor.

Identifiers

Classification

classification.v_security_classification

Asset class: Equity
Sector: Health Care
Industry: Pharmaceuticals
Source: LLMunreviewed
Self-reported confidence: 0.95
Model: deepseek
Rationale: The company is a pharmaceutical preparation firm as indicated by its SIC code and business focus.

Classifications are unreviewed model output. All 5,771 assignments carry source = LLM and is_reviewed = false. Confidence is the model’s own estimate and is not calibrated — it clustered at 0.90–0.98 across the whole first pass, including rows that later proved wrong. Use it to order a review queue, not as a probability. Two share classes of one issuer can disagree.

Classification

Fund data

Not linked to a fund series.

Either this is not a fund, or it is one the SEC share-class snapshot cannot reach — commodity trusts and notes have no series ID at all.